Scoop: Cell­Prothera eyes $30M round for PhI­II tri­al of cell ther­a­py for heart at­tacks: #Jef­feries23

Cell­Prothera plans to raise around $30 mil­lion in its first ma­jor fundraise to help ad­vance its lead re­gen­er­a­tive cell ther­a­py pro­gram for pa­tients who have re­cent­ly ex­pe­ri­enced heart at­tacks in­to reg­is­tra­tional de­vel­op­ment, End­points News has learned.

“We want to do the Phase III tri­al in both the US and EU, so we ex­pect we need to raise as much as we’ve raised to date over sev­er­al tranch­es, but this time in a sin­gle shot,” CEO Matthieu de Kalber­mat­ten told End­points on Tues­day at the an­nu­al Jef­feries health­care con­fer­ence in Lon­don.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER